Armed with the world’s largest virus-bacteria interactome repository, Phase Genomics to engineer a predictive engine for the development of new therapies against drug-resistant biothreats

SEATTLE, June 09, 2022--(BUSINESS WIRE)--Phase Genomics, Inc., a leading developer of proximity ligation-based genomic solutions, today announced $5.5MM in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases (NIAID). With the new funding, Phase Genomics will leverage its world’s largest phage-bacteria interactome repository to power the development of a unique AI-driven predictive engine for therapeutic phage discovery.

Phages are viruses that prey on bacteria and a promising tool in humanity’s battle against antibiotic resistant infections. Despite being the most abundant form of life on earth, few interactions between phages and their targets are currently documented. Phase Genomics’ proprietary technology captures virus-host interactions directly within microbial communities, without the need for culturing, allowing for rapid discovery of hundreds of new phages and their targets from even single samples.

The new financing, which includes a $3.5MM grant from the Gates Foundation and a $2MM SBIR award from NIAID, will allow Phase Genomics to harness its proximity-guided metagenomics platform, ProxiMetaTM, to develop the world’s largest atlas of phage-bacteria interactions and use machine learning tools to identify phages that can be used in therapeutic settings such as C. difficile infections, Ulcerative colitis, and Crohn’s disease. This technology will also empower improved monitoring of wastewater for resistant pathogens.

"We are truly at the frontier of a new understanding of how to improve the human condition," said Ivan Liachko, PhD, founder and CEO of Phase Genomics. "The potential to leverage the knowledge of how viruses and bacteria interact is immense. Combined efforts with our strategic partners will help develop a global biodefense shield for pandemic prevention. We plan for the new phage atlas to serve as a resource to help combat pathogen outbreaks and other biological threats, including drug resistance caused by the overuse of antibiotics."

Antimicrobial resistant (AMR) infection is a leading cause of intractable disease. Global health experts project that it will add $1.2 trillion to yearly global health expenditures and surpass cancer as a leading cause of death by 2050.

Broad visibility into global microbial populations enables prediction of potential sources of AMR outbreaks before they occur. It can also predict the severity of epidemics, as well as aid in the development of protective measures, like phage-based therapies. Phase Genomics will use the funding to extend its AMR atlas’ reach through international sample collection at scale to monitor the proliferation of mobile genetic elements bearing resistance traits in disparate bacterial communities.

"Phage therapeutics are a promising avenue to overcoming the looming public AMR health crisis, but our limited understanding of virus-microbe interaction and bacterial host range is a significant barrier to the advancement of this technology," said Chris Mason, PhD, professor and renowned geneticist. "By combining machine learning tools with a vast repository of phage interactome data we’ll finally shed light on a vast scientific blind spot that will help advance global public health and help mitigate against the catastrophe of future pandemics."

A recent study published in Nature Biotechnology demonstrates the power of Phase Genomics’ unique technology. Researchers, using Phase Genomics’ ProxiMetaTM metagenome deconvolution platform, were able to describe lineage-resolved microbial communities, aligning mobile genetic elements with host genomes and identifying hundreds of novel phage-host associations in a single microbiome sample.

Follow Phase Genomics on Twitter and LinkedIn for the latest news and information.

Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, they also offer an industry-leading genome and metagenome assembly and analysis software.

Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005985/en/

Eric Schudiske eric@s2spr.com

Innergex Renewable Energy Inc. (TSX: INE) ("Innergex" or the "Corporation") announces it has completed the acquisition of 100% of the ordinary shares of Aela Generación S.A. and Aela Energía SpA (together "Aela"), a 332 MW portfolio of three newly-built operating wind assets in Chile, for a purchase price of US$685.6 million (CAN$861.2 million).

Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.

Novavax's authorization timeline differs from other first-time applicants, and ongoing submission of manufacturing data has given the FDA reason to slow the process.

The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.

After securing a place in a European program designed to accelerate the process of getting medicines to patients with unmet medical needs, a Durham-based pharmaceutical company has landed a spot in a similar U.S. program. BioCryst Pharmaceuticals (Nasdaq: BCRX) announced Wednesday the U.S. Food and Drug Administration has granted its investigational drug, called BCX9250, a fast track designation. The company is developing BCX9250 for patients with fibrodysplasia ossificans progressiva, or FOP, a very rare genetic connective tissue disorder.

GSK plc (NYSE: GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. An Independent Data Monitoring Committee reviewed the interim analysis, and the primary endpoint was exc

Launch and space systems company Rocket Lab USA Inc. has been selected by Ball Aerospace to manufacture the solar array panel to power NASA’s Global Lyman-Alpha Imager of Dynamic Exosphere (GLIDE) mission spacecraft planned to launch in 2025.

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

(Bloomberg) -- Bluebird Bio Inc. was supposed to be different.Most Read from BloombergEating Two Portions of Fish Per Week Linked to Deadly Skin CancerUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenFive Key Moments From the Jan. 6 Capitol Riot HearingWhy Inflation Is Hitting American Households Like Never BeforeUS Lifts COVID-19 Test Requirement for International TravelThe Boston-area company aimed to develop gene therapies for rare conditions that traditionally require extensive

Eli Lilly and Novo Nordisk have powerful new medicines for weight loss. Wall Street predicts massive sales.

Bavarian Nordic is the only company with a vaccine approved by the Food and Drug Administration. Its plant is closed until August.

Stratolaunch says the sixth flight test of its super-sized Roc carrier airplane ended earlier than planned when the team ran into an unexpected issue. “While completing Roc testing operations, we encountered a test result that made it clear we would not achieve all objectives for this flight,” the California-based company, which was created by Microsoft co-founder Paul Allen more than a decade ago, said in Twitter update. “We made the decision to land, review the data, and prepare for our next f

Tuesday was a crucial day for Novavax (NASDAQ: NVAX). At long last, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) met to review the company's COVID-19 vaccine data. A negative recommendation from the FDA advisory committee held the potential to deliver a crushing blow.

At the beginning of the COVID pandemic, it was widely believed that if you survived an infection from the coronavirus, you were safe from getting it again. Since then we've learned that you can get reinfected—sometimes many times, and particularly with different variants. It's also become clearer than ever that the protection from vaccination alone isn't a surefire way to prevent you from getting COVID again (and again). While researchers are still working to understand more about COVID reinfect

Novavax’s Covid-19 vaccine, unlike the Pfizer and Moderna ones, uses a well-established, protein-based approach.

The drug is one of two developed by the Somerville gene therapy company that the advisory committee will weigh this week.

Cold cereal is a widly popular breakfast choice in America. According to data reported by Statista in July 2021, 283 million of us pour a bowl to get the day started (compared with only about 50 million who don't). But lately, multiple well-loved breakfast cereal brands have come under scrutiny, with consumers complaining that these widely available and decades-old names are making them sick. Read on to find out the latest brand coming under fire and what unhappy customers say it's doing to thei

Abbott Laboratories (NYSE: ABT) is a top healthcare stock that's been in the news recently for its role in the U.S. baby formula shortage. When Abbott reported its results for the first three months of the year, it noted that it initiated a voluntary recall of infant formula products in February. The result was a troubling result for its nutrition segment, where sales of $1.9 billion declined by 7% year over year.

But it's not significant enough to prevent the space telescope from helping us observe the universe.

Level up your grilling game with these dietitian-approved franks, including beef, pork, chicken, turkey and vegetarian options.